Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:05:45.382Z.
Calculation as of: 2026-10-06T15:05:45.382Z.
Quote observation: 2026-10-06T15:05:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$665.40M
EV/EBIT Ratio
60.69x
TTM Avg
21.67x
3Y Avg
25.85x
5Y Avg
35.25x
Market Cap
$665.48M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$609.24M
EV/EBIT Ratio
N/A
TTM Avg
596.45x
3Y Avg
263.81x
5Y Avg
279.32x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $642.86M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $640.05M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $637.30M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $665.40M | 60.69x | 21.67x | 25.85x | 35.25x |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $665.48M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $609.24M | N/A | 596.45x | 263.81x | 279.32x |
| Helus Pharma Inc. (HELP)vs › | $671.29M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $622.01M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $682.40M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $601.74M | N/A | 2.85x | 52.42x | 52.42x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
